Open access · CC-BY
via OpenAlex
Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone–brain aging
Man Yu, Yu Wu, Ao Wang, Mei Wang, Yao Chen, Hang Ren, Yixin Zhang, Yingjie Liu, Shudong Wang, Xu Fan
Frontiers in Immunology · 2026
Dysbiosis
Mitochondrial dysfunction
Cellular senescence
Altered intercellular communication
Chronic inflammation
Senolytics
Human
Mouse
Preclinical / animal
Review
Abstract
Background: Global population aging has driven a marked rise in the co-prevalence of osteoporosis and cognitive impairment, and a bidirectional epidemiological association between the two conditions is now supported by multiple meta-analyses. The shared biological mechanisms underlying this comorbidity, however, remain incompletely defined, and the two disorders continue to be managed within largely separate clinical disciplines. Aim and scope: This review consolidates existing evidence into an integrative immunopathological framework in which inflammaging(definition)-the chronic, low-grade, sterile systemic inflammatory state driven by senescent cells and their senescence(definition)-associated secretory phenotype (SASP)-is examined as a shared upstream driver that concurrently reconfigures skeletal remodeling and central neuroimmune dynamics through the bone-brain axis. We do not claim to identify novel molecular targets; rather, we synthesize an integrative perspective that has been treated in disciplinary silos. Key mechanistic themes: At the molecular level, persistently elevated SASP-derived cytokines (IL-6, IL-1β, TNF-α) engage RANKL-dependent osteoclastogenesis in bone and prime microglial neuroinflammation in the central nervous system. Chronic NF-κB signaling and NLRP3 inflammasome activation, amplified in preclinical models by mitochondrial DNA release via the cGAS-STING axis, sustain this dual pathological output. Within the bone-brain axis, bone-derived endocrine signaling is remodeled during aging: osteocalcin (OCN) secretion declines, while osteocyte-derived sclerostin (SOST) rises and may antagonize Wnt/β-catenin signaling in both compartments. Blood-brain barrier disruption and peripheral immune-cell infiltration further amplify central neuroinflammation. Balanced appraisal: We explicitly distinguish (i) conceptual hypotheses, (ii) preclinical (cellular and rodent) findings, and (iii) validated human data. Several widely cited mechanisms-including OCN-GPR158-mediated neuroprotection, cGAS-STING-driven neuroinflammation, and microbiome-based longevity signatures-rest predominantly on murine models or single cohorts and require independent human validation. Microglial responses in the aging brain reflect a heterogeneous state space rather than a uniform pro-inflammatory conversion. Therapeutic implications: Candidate bone-brain dual-targeting interventions-senolytics(definition) (dasatinib plus quercetin), NLRP3 inhibitors, cGAS-STING blockade, GLP-1 receptor agonists, and microbiota-targeted strategies-are discussed with explicit reference to current evidence level, safety concerns, and translational limitations, rather than as established co-therapies. Dual-endpoint randomized trials enriched for elevated inflammaging biomarkers are needed before any of these agents can be positioned for clinical use in bone-brain comorbidity. Conclusion: The inflammaging-centered framework advanced here provides a testable integrative pathophysiological perspective on bone-brain aging comorbidity and a rationale for interdisciplinary "bone-brain integrated" clinical evaluation in older adults, which we frame as an aspirational, hypothesis-generating model rather than an evidence-based standard of care.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fimmu.2026.1874465
- Canonical
- link ↗
- Fetched
- 2026-10-06 MST
Cite this
APA
Yu, M., Wu, Y., Wang, A., Wang, M., Chen, Y., Ren, H., Zhang, Y., Liu, Y., Wang, S., & Fan, X. (2026). Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone–brain aging. <em>Frontiers in Immunology</em>. https://doi.org/10.3389/fimmu.2026.1874465
Vancouver
Yu M, Wu Y, Wang A, Wang M, Chen Y, Ren H, et al. Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone–brain aging. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1874465.
BibTeX
@article{man2026Chroni,
title = {Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone–brain aging},
author = {Man Yu and Yu Wu and Ao Wang and Mei Wang and Yao Chen and Hang Ren and Yixin Zhang and Yingjie Liu and Shudong Wang and Xu Fan},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1874465},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in immunology 2026
Open access · OA
Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone-brain aging.
Diseases (Basel, Switzerland) 2026
Open access · OA
Cellular Senescence in Idiopathic Pulmonary Fibrosis: Molecular Mechanisms, Pathogenic Networks, and Emerging Therapeutic Targets.
European Journal of Translational Myology 2026
Open access · CC-BY
Abstract 062 | Mitochondrial signaling in age-related conditions
Fitoterapia 2026
Citation only
Berberine as a multi-hallmark modulator of aging: From AMPK and mitophagy to inflammaging and the SASP.
Nutrients 2026
Open access · CC-BY
Dietary Polyphenols in Brain Aging: Molecular Mechanisms and Implications for Neurodegeneration
Molecules 2022
Open access · CC-BY